Drug Type Small molecule drug |
Synonyms 普卢格列汀二甲双胍 |
Target |
Action inhibitors, modulators, activators |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors), GPD1 modulators(glycerol-3-phosphate dehydrogenase 1 modulators), PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseIND Approval |
First Approval Date- |
Regulation- |
Molecular FormulaC4H11N5 |
InChIKeyXZWYZXLIPXDOLR-UHFFFAOYSA-N |
CAS Registry657-24-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | IND Approval | China | 18 Apr 2025 |